Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT03346135 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Myeloma
Secondary Amyloidosis

Interventions

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation
BIOLOGICAL: Daratumumab
OTHER: Laboratory Biomarker Analysis
DRUG: Melphalan

Sponsor

City of Hope Medical Center

Collaborators

[object Object]